Press release, Oss, November, 02, 2018

Kinase inhibitors illustrate the successful translation of basic scientific knowledge of cancer into new targeted therapies. Selecting the right patient population based on the occurrence of specific cancer driver events is key. Read all about it on the website of NTRC.